Aigen Investment Management’s Corcept Therapeutics CORT Stock Holding History

Aigen Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,292	Closed	-$407K	–	870
2023 Q2	$407K	Buy	+18,292	New	+$421K	0.06%	400
2022 Q4	–	Sell	-11,677	Closed	-$299K	–	569
2022 Q3	$299K	Buy	+11,677	New	+$312K	0.04%	401
2022 Q1	–	Sell	-10,128	Closed	-$201K	–	642
2021 Q4	$201K	Buy	+10,128	New	+$205K	0.01%	932
2020 Q4	–	Sell	-83,599	Closed	-$1.46M	–	817
2020 Q3	$1.46M	Sell	83,599 -57,220	-41%	-$912K	0.19%	168
2020 Q2	$2.37M	Buy	140,819 +123,703	+723%	+$1.74M	0.3%	76
2020 Q1	$204K	Buy	+17,116	New	+$212K	0.03%	706

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Aigen Investment Management's CORT Position: Q3 2023 in Review

Aigen Investment Management sold out of Corcept Therapeutics (CORT) in Q3 2023, closing a stake of 18,292 shares — an estimated $407K sold.

Aigen Investment Management first reported a position in CORT in Q1 2020 and held it in 6 quarters. The position peaked at $2.37M in Q2 2020. 246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

Aigen Investment Management reported no remaining Corcept Therapeutics position as of Q3 2023 after selling out during the quarter.
Aigen Investment Management sold 18,292 Corcept Therapeutics shares in Q3 2023, an estimated $407K.
Aigen Investment Management first reported a position in Corcept Therapeutics in Q1 2020 and held it in 6 quarters.
Aigen Investment Management's Corcept Therapeutics position peaked at $2.37M in Q2 2020.
246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on Aigen Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.